Recently a bio-artificial liver (BAL) system has been developed at the Academic Medical Center (AMC) of Amsterdam to bridge patients with acute liver failure (ALF) to orthotopic liver transplantation (OLT). After successful testing of the AMC-BAL in rodents and pigs with ALF, a phase I study in ALF patients waiting for (OLT) was started in Italy. We present the safety outcome of the first 7 patients aged 21-56 years with coma grade III or IV The total AMC-BAL treatment time ranged from 8 to 35 hours. Three patients received 2 treatments with two different BAL's within three days. Six of the 7 patients were successfully bridged to OLT. One patient showed improved liver function after two treatments and did not need OLT. No severe adverse events of the BAL treatment were noted. CONCLUSION: Treatment of ALF patients with the AMC-BAL is a safe and feasible technique to bridge the waiting time for an adequate liver-graft.

van de Kerkhove, M., Di Florio, E., Scuderi, V., Mancini, A., Belli, A., Bracco, A., et al. (2002). Phase I clinical trial with the AMC-bioartificial liver. INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 950-959.

Phase I clinical trial with the AMC-bioartificial liver.

Dauri, M;TISONE, GIUSEPPE;
2002-01-01

Abstract

Recently a bio-artificial liver (BAL) system has been developed at the Academic Medical Center (AMC) of Amsterdam to bridge patients with acute liver failure (ALF) to orthotopic liver transplantation (OLT). After successful testing of the AMC-BAL in rodents and pigs with ALF, a phase I study in ALF patients waiting for (OLT) was started in Italy. We present the safety outcome of the first 7 patients aged 21-56 years with coma grade III or IV The total AMC-BAL treatment time ranged from 8 to 35 hours. Three patients received 2 treatments with two different BAL's within three days. Six of the 7 patients were successfully bridged to OLT. One patient showed improved liver function after two treatments and did not need OLT. No severe adverse events of the BAL treatment were noted. CONCLUSION: Treatment of ALF patients with the AMC-BAL is a safe and feasible technique to bridge the waiting time for an adequate liver-graft.
2002
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/18 - CHIRURGIA GENERALE
English
van de Kerkhove, M., Di Florio, E., Scuderi, V., Mancini, A., Belli, A., Bracco, A., et al. (2002). Phase I clinical trial with the AMC-bioartificial liver. INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 950-959.
van de Kerkhove, M; Di Florio, E; Scuderi, V; Mancini, A; Belli, A; Bracco, A; Dauri, M; Tisone, G; Di Nicuolo, G; Amoroso, P; Spadari, A; Lombardi, G...espandi
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

Questo articolo è pubblicato sotto una Licenza Licenza Creative Commons Creative Commons

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/23240
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 157
  • ???jsp.display-item.citation.isi??? 117
social impact